Summary
OVERALL: PROJECT SUMMARY Our primary goal in this IPCAVD program is to develop a germline-targeting priming immunogen for the HIV Envelope V2-apex broadly neutralizing antibody (bnAb) site. We aim to test its ability to activate V2-apex bnAb precursors in preclinical animal models and manufacture it under GMP standards for human clinical testing. To address this comprehensively, in this IPCAVD grant proposal we have assembled a highly skilled team of investigators with expertise in rational protein design, bioengineering, B and T cell immunology, vaccine evaluation models, antibody discovery,
